NIVF
Live News • Jul 06
NewGenIvf Group Gains $19 Million Big Four Validation for UAE Cytometry Launch NewGenIvf Group announced that a Big Four firm has valued its planned UAE-based cell sorting and cytometry leasing business at about US$19 million, and appointed industry veteran Nadeem Malik as Senior Strategic Advisor to lead the UAE/GCC expansion.
The company plans to target the GCC fertility market by combining its advanced cytometry platform with demand driven by high infertility rates and medical tourism in the UAE, potentially adding a new revenue stream alongside its existing IVF operations.
NewGenIvf Group’s stock trades at about $1.38, with the share price down 94.3% year to date, suggesting the market is currently pricing in considerable execution and funding risk around new projects.
This development puts the UAE/GCC cytometry rollout in focus. Key questions include how quickly NewGenIvf Group can convert the US$19 million project valuation into signed leasing contracts and whether that traction will be enough to shift sentiment after a steep share price decline. Announcement • Jun 11
NewGenIvf Group Limited Announces Board Appointments NewGenIvf Group Limited announced the appointments of Ms. Lee Sze Mun, Mr. Lau Tsz Hin Vincent, Mr. Lam Chun Tung Patrick, and Mr. Cheung Kong Yiu as independent directors to its Board of Directors. Ms. Lee Sze Mun's appointment took effect as of June 1, 2026, and Mr. Lau Tsz Hin Vincent's, Mr. Lam Chun Tung Patrick's, and Mr. Cheung Kong Yiu's appointments took effect as of June 8, 2026. Ms. Lee has served as an independent director of NewGenIvf since June 1, 2026. With over 22 years of experience in financial accounting, taxation, and group consolidation, she is a Fellow Member of ACCA (FCCA) and holds a BA (Hons) in Accounting and Finance from Leeds Beckett University (formerly Leeds Metropolitan University). Ms. Lee currently serves as Assistant Manager (Finance Control) at a statutory body responsible for regulating and overseeing retirement schemes. Her previous experience includes senior finance roles at a construction company that primarily undertakes government projects, as well as at a German-based multinational shipowner. She also brings audit assurance experience gained from working at a registered CPA firm. Mr. Lau has served as NewGenIvf's independent director since June 8, 2026. Since 2025, he has served as Co-Founder and Chief Operating Officer of K25.ai. From 2024 to 2025, he served as Vice President, Business Strategy Office at OSL Group. From 2019 to 2023, he served at OKEx, Bitfinex and Digital Vision Brands. Mr. Lau holds a Bachelor of Business Administration. Mr. Lam has served as NewGenIvf's independent director since June 8, 2026. Since 2025, he has served as Co-Founder and Chief Strategy Officer of K25.ai. From 2023 to 2025, he served as a Quantitative Trader at Keyrock S.A. From 2020 to 2022, he served at HKEX across listed issuer regulation, strategy and data governance. Mr. Lam holds a Bachelor of Science in Risk Management and Business Intelligence. Mr. Cheung has served as NewGenIvf's independent director since June 8, 2026. Since 2024, he has served as Founder and Chief Executive Officer of K25.ai. From 2025 to 2026, he served as a Board Member of Prenetics Global Limited. From 2017 to 2020, he served as Chief Operating Officer of OKEx. Earlier in his career, he held senior leadership roles at iClick Interactive and Groupon. Mr. Cheung holds a Bachelor of Information Technology. Announcement • Jun 06
NewGenIvf Group Limited (NasdaqCM:NIVF) exercised its top-up option to acquire an additional 4% stake in PredicXion Group Limited for $3.3 million. NewGenIvf Group Limited (NasdaqCM:NIVF) exercised its top-up option to acquire an additional 4% stake in PredicXion Group Limited for $3.3 million on June 2, 2026. As part of consideration, $2 million will be paid in cash and 1.5 million newly issued Class A ordinary shares of NewGenIvf Group Limited. Upon completion, NewGenIvf Group Limited will own 6% stake in PredicXion Group Limited.
The transaction is subject to obtaining all corporate, regulatory, Nasdaq, SEC and third-party approvals. 
